The Latest on Multiple Sclerosis and COVID-19 Vaccines The Latest on Multiple Sclerosis and COVID-19 Vaccines

Dr Stephen Krieger on how effective vaccines are in these patients, who should receive boosters, and when.Medscape Neurology
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery Commentary Source Type: news

Related Links:

Discussion: Clinical and radiological findings in these cohort of MS patients confirmed disease re/activation and suggested a temporal association between disease activity and COVID-19 vaccination. The nature of this temporal association, whether causative or incidental, remains to be established.
Source: Frontiers in Neurology - Category: Neurology Source Type: research
Vaccine administration may be involved in the development of some central nervous system demyelinating diseases. The COVID-19 vaccine is being administered to the entire population, but to date, little association between vaccination and the risk of developing multiple sclerosis (MS) has been suggested, and only a few case reports have been published. Here, we present a 40-year-old woman who developed cervical myelitis after receiving the COVID-19 vaccine. Myelitis was considered the initial clinical manifestation of MS.
Source: Journal of Neuroimmunology - Category: Allergy & Immunology Authors: Tags: Short Communication Source Type: research
AbstractMultiple Sclerosis (MS) has long been considered a T-cell-mediated autoimmune disease of the central nervous system. However, newer evidence shows that B cells play a crucial role in the pathogenesis of MS via antibody production, antigen presentation, T cell stimulation and activation, and production of pro-inflammatory cytokines. Developing B cells express the CD20 molecule from the pre-B cell to the plasmablast stage, and the anti-CD20 monoclonal antibodies rituximab, ocrelizumab, ofatumumab and ublituximab are either in use or are being developed for treatment of MS as B cell-depleting therapies. They have show...
Source: Clinical and Experimental Neuroimmunology - Category: Neurology Authors: Tags: INVITED REVIEW Source Type: research
Condition:   PWMS Who Have Completed Vaccination Against COVID-19 and Test Negative for COVID-19 Spike Protein Antibodies Using a Commercial Assay Interventions:   Biological: Homologous booster;   Biological: Heterologous booster Sponsors:   Griffin Hospital;   Yale-Griffin Prevention Research Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Since early December 2019, the Coronavirus Disease 19 (COVID-19), the disease caused by the virus Sars-Cov-2, has devastated communities on a global scale, infected over 200 million people, and caused over 4.3 million deaths worldwide [1]. In December 2020, the FDA approved two mRNA vaccines for Sars-Cov-2. After tiresome effort by healthcare workers around the world, over 4.7 billion doses of the vaccine have been administered as of August 2021 [1].
Source: Journal of the Neurological Sciences - Category: Neurology Authors: Tags: Review Article Source Type: research
The statement concludes that COVID-19 vaccines are safe for patients with multiple sclerosis and that most MS patients gain the same protection as the general population. But there are exceptions.Medscape Medical News
Source: Medscape Infectious Diseases Headlines - Category: Infectious Diseases Tags: Neurology & Neurosurgery News Source Type: news
Basel, 13 October 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new long-term data that reinforce the benefit of early initiation and ongoing treatment of OCREVUS® (ocrelizumab) on disability progression in relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS), as well as safety outcomes for an analysis of shorter 2-hour infusion in minority populations. OCREVUS data from all clinical trials consistently show a favourable benefit-risk profile over eight years. Roche and research partners will also present four late-breaking abstracts to share the latest data regarding COVID-19 and vacci...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
Condition:   Multiple Sclerosis Intervention:   Biological: COVID-19 vaccination Sponsors:   Sheba Medical Center;   Sanofi Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Brain | COVID-19 | Multiple Sclerosis | Neurology | Neurosurgery | Vaccines